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April 9, 2013:1549–54ing cyanosis. Most of the patients in Rogers et al. (1) had
ypoplastic left heart syndrome (HLHS). Therefore, the authors
all the Norwood procedure stage 1, cavopulmonary shunt (CPS)
lacement is stage 2, and the Fontan completion is stage 3
alliation. In this frame of reference, the authors unwittingly may
e extending HLHS terminology to all other single ventricular
iagnoses. These different diagnoses call for various different
rocedures before the Fontan operation either to augment or to
educe the pulmonary circulation, but all resulting in a ventric-
lar volume overload. It is the initiation of the Fontan circula-
ion, which normalizes ventricular preload, that is the crucial
tep in altering fundamentally the circulation and ventricular
reload. In the current era, this initiation is the CPS placement,
hich is for that reason the first stage of Fontan palliation and
s where outcome analyses should start. Fontan completion
inferior caval to pulmonary connection) does not alter ventric-
lar preload.
It used to be customary to institute a Fontan circulation in a
ingle operation, associated with 1 early-stage mortality and no
nterstage mortality. However, in staged procedures, interstage
ortality can be substantial (2). Hence it seems odd, in the Rogers
t al. (1) paper, to combine 21 1-stage Fontan procedures with
nly the second stage of the other patients. Ignoring first-stage and
nterstage mortality in such an analysis conceals the genuine
-stage Fontan mortality rates. The relatively low mortality rate in
he Rogers et al. paper (1) is influenced strongly by ignoring the
ortality associated with CPS placement and the interstage period.
uch more could have been concluded from this dataset if patients
ere entered at the initiation of the Fontan circulation, which is at the
PS placement.
Finally, in response to their excellent early survival after second-
tage Fontan procedure, we are curious how their Fontan patients
re doing currently. Because the Rogers et al. (1) study deals with
8 years of operations, it would have been interesting to see the
ong-term attrition in the Fontan circulation.
In conclusion, reporting only the outcome of the second stage of
2-stage Fontan circulation, as in this paper, sheds no light on the
eal issues at stake, specifically results including the entire Fontan
alliative sequence. Calling CPS placement a second-stage palli-
tion before the real Fontan seems to us an obfuscated paradigm
hift, because the Fontan circulation actually has started with the
PS placement.
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We thank the correspondents for their interest in our recent paper
concerning post-operative outcomes after the Fontan operation
(1). Our goal in reviewing our experience was to identify risk
factors for morbidity and mortality at the time of Fontan surgery.
Although the creation of a total cavopulmonary connection
(TCPC) was performed as a single procedure for a number of
years, that strategy was abandoned because of substantial morbidity
and mortality with the combined procedure. It is now well
established that creating a total cavopulmonary connection in 2
separate operations results in significantly improved outcomes.
Indeed, in our cohort, more than 97% of subjects had a superior
cavopulmonary connection (SCPC) before Fontan surgery.
With due respect to the correspondents, we posit that although
ventricular unloading of the systemic ventricle does begin after
SCPC, there remain substantial differences between the circulation
after SCPC and the circulation after the Fontan operation. After
SCPC, oxygen saturations remain significantly lower than normal,
which may lead to the formation of systemic to pulmonary collateral
vessels and may mitigate the impact of ventricular unloading. Further,
after SCPC, venous flow from the inferior extremities returns to the
heart in the usual fashion, whereas after the Fontan operation, all
venous return, with the exception of fenestration flow, must traverse
the pulmonary vascular bed. This likely has implications for the
distribution of blood flow and may limit cardiac filling.
In this paper, we focused on early outcomes after the Fontan
operation. An evaluation of outcomes over the course of the entire
single ventricle palliative pathway would have to include the
outcome after SCPC along with the outcome up until SCPC,
which may include a Norwood type reconstruction, a systemic to
pulmonary arterial shunt, a pulmonary arterial band, or close
observation without surgical intervention. We do not believe that
grouping SCPC with the Fontan operation is necessary or appro-
priate when evaluating the post-operative outcome of the Fontan
operation itself. The physiological features after SCPC are differ-
ent from those after the Fontan operation, and we believe that the
factors associated with outcomes for each procedure should be
evaluated separately. Although our data do not describe an overall
morbidity and mortality for the entire course of single ventricle
palliation, they do provide important information regarding patient
and procedural factors associated with short-term morbidity and
mortality after the Fontan operation, information relevant to all
patients being considered for total cavopulmonary connection. With
regard to the long-term outcome after Fontan surgery, we agree that
this is an important issue that warrants attention, but this review was
focused on perioperative and early post-operative outcomes.
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Are Omega-3 Fatty Acids
Ineffective for Preventing
Atrial Fibrillation Recurrence?
We read with great interest the paper by Macchia et al. (1). The
FORWARD (Randomized Trial to Assess Efficacy of PUFA for
the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation)
trial involving 586 participants with symptomatic atrial fibrillation
(AF) who already recovered normal sinus rhythm before being
included in the study. There was no significant difference between
the patients randomized to placebo or to omega-3 fatty acids for
symptomatic recurrence of AF. The authors concluded that sup-
plementation with 1 g of omega-3 fatty acids for 1 year did not
reduce recurrent AF.
Are omega-3 fatty acids really ineffective for the prevention of
atrial fibrillation recurrence? A meta-analysis indicated that in
patients (3 studies and 485 patients) administered omega-3 fatty
acids at least 4 weeks before cardioversion and continued thereaf-
ter, the recurrence rate of AF was obviously low (2). Metcalf et al.
(3) demonstrated omega-3 fatty acids incorporated into human
atrial cell membrane and reached a peak at about 30 days of
treatment. Though omega-3 fatty acids can be increased in plasma
and atrial tissue in short-term application, the concentration may
be insufficient to develop the best antiarrhythmic effect (4).
However, the patients in the FORWARD study were given
omega-3 fatty acids started after cardioversion. So, maybe the
duration of application before cardioversion is vital for its role.
Therefore, on the basis of current evidence we still can not reach
a definite conclusion whether omega-3 fatty acids is effective for
AF recurrence. Future large-scale, high-quality studies with pa-
tients being given omega-3 fatty acids at least 4 weeks prior to
cardioversion are needed to verify our speculation and give a
comprehensive evaluation of omega-3 fatty acids.
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We appreciate the letter of Dr. Guo and colleagues in which they
raised doubts about if we can be definitive in closing the debate
regarding the lack of efficacy of polyunsaturated fatty acids (n-3
PUFA) for the prevention of atrial fibrillation (AF). The authors
raised an important and legitimate concern mentioning that
omega-3 fatty acids may require time to be effectively in-
corporated into human cell membrane. Small systematic reviews
seem to confirm this fact (1).
However, we still think that oral supplementation with n-3
PUFA is ineffective for at least 2 reasons. First, our updated and
large systematic review that included 1,990 patients and 894 events
(2) failed—in a meta-regression analysis—to find any association
between supplementation and AF relapse, and disproved any
relationship among dose amount, time of loading, or use of other
antiarrhythmic therapies. Second, patients in the FORWARD
(Randomized Trial to Assess Efficacy of PUFA for the Mainte-
nance of Sinus Rhythm in Persistent Atrial Fibrillation) trial (3)
who received more than 30 days of “loading dose” of n-3 PUFA
(those who did not have a recurrence within the first month of
follow-up) presented the same rate of AF recurrence than those
who did not receive omega-3.
In any case, we cannot affirm that a large and “definitive”
clinical trial should not be conducted. However, we think
that—in the context of secondary prevention of AF—we do
have now strong evidence suggesting that oral supplementation
should not be initiated to prevent AF relapse. On the other
hand, this hypothesis is still untested in the setting of primary
prevention of AF. In this context, large clinical trials may be
conducted.
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